H.R. 9675: Expanding Opportunities for Recovery Act of 2026

This bill would create a federal grant program for states to expand access to treatment for opioid abuse, dependence, and addiction. The grants would be administered by the Assistant Secretary for Mental Health and Substance Use through the Center for Substance Abuse Treatment.

What states could use the grants for

States receiving grants would have to use them to provide clinically appropriate opioid treatment services. The bill says these services should be:

• Evidence-based, such as medication-assisted treatment.
• Based on a doctor or clinician’s recommendation, so people receive the level of care considered medically necessary.
• Limited to certain groups: people without health insurance, or people whose insurance does not cover the needed services or places barriers in the way of getting them.
• Limited in duration: the grant money could not be used to pay for more than 60 consecutive days of treatment for any one person.

How medications could be used

The bill would allow states to include medications as part of treatment, but only if the medications:

• Are legally marketed under federal law,
• Are clinically appropriate for the person’s condition, and
• Are offered in a way that respects consumer choice.

The bill says medications would be used along with other treatment, not as the only requirement in all cases.

Insurance-related rules

The bill is aimed at people who do not have adequate insurance coverage for opioid treatment. It specifically covers people whose insurance either does not cover the services or creates barriers such as:

• Limiting coverage to a certain time period, or
• Requiring less intensive or less expensive treatment first, even when a clinician recommends more intensive care like inpatient or residential treatment.

Reporting and oversight

States that get grants would have to report on outcomes such as:

• Reductions in substance use,
• How long people stay in treatment,
• Whether people are connected to the next appropriate level of care, and
• Changes in involvement with criminal justice activities.

They would also report data on how long people receive clinically appropriate treatment and how often medication-assisted treatment is used. The federal agency would evaluate the program, share the results with Congress, and post them publicly online. The agency would also provide technical assistance to states.

Program coordination and funding

The bill would require the new grant program to be coordinated with existing federal substance abuse prevention, treatment, and recovery support programs. It also reserves 5 percent of the funds appropriated for the program each fiscal year for evaluation, information sharing, and technical assistance.

Relevant Companies

• ABBV — AbbVie may be indirectly affected because its opioid use disorder treatment products could see changes in demand if more patients receive medication-assisted treatment through state grant programs.
• INDV — Indivior could be indirectly affected because it sells medications used in opioid addiction treatment, which may be used more often under expanded access programs.
• ACAD — Acadia Healthcare could be indirectly affected if more people seek inpatient or residential substance use treatment services that the bill may help fund for uninsured or underinsured patients.